Skip to main content

Table 5 Prognostic factors in univariate analysis for progression free survival (PFS) and Overall Survival (OS). Data reported are the median survival time for the various groups and the statistical significance

From: Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

  3DCRT p VMAT p
Overall survival
 Agea a: 1.33 ± 0.09
b: 1.06 ± 0.19
0.04 a: 1.59 ± 0.23
b: 1.25 ± 0.21
0.12
 KPSb a: 1.06 ± 0.50
b: 2.03 ± 0.53
<0.001 a: 1.03 ± 0.09
b: 2.95 ± 0.51
<0.001
 Histologyc a: 3.11 ± 0.60
b: 1.11 ± 0.06
<0.001 a: 3.62 ± 0.39
b: 1.25 ± 0.09
<0.001
 EORd a: 1.82 ± 0.31
b: 1.02 ± 0.04
<0.001 a: 2.68 ± 0.44
b: 1.19 ± 0.12
<0.001
 MGMTe a: 1.19 ± 0.06
b: 1.48 ± 0.45
0.002 a: 1.23 ± 0.13
b: 1.99 ± 0.27
0.009
Progression free survival
 Agea a: 1.10 ± 0.11
b: 0.82 ± 0.25
0.02 a: 1.37 ± 0.24
b: 0.97 ± 0.08
0.06
 KPSb a: 0.86 ± 0.04
b: 2.01 ± 0.44
<0.001 a: 0.83 ± 0.09
b: 2.78 ± 0.59
<0.001
 Histologyc a: 2.77 ± 0.57
b: 0.93 ± 0.05
<0.001 a: 3.51 ± 0.42
b: 0.99 ± 0.09
<0.001
 EORd a: 1.68 ± 0.34
b: 0.83 ± 0.06
<0.001 a: 2.58 ± 0.5
b: 0.92 ± 0.16
<0.001
 MGMTe a: 0.95 ± 0.04
b: 1.40 ± 0.36
0.02 a: 0.98 ± 0.12
b: 1.70 ± 0.44
0.02
  1. Abbreviations: 3DCRT 3 dimensional conformal radiotherapy, VMAT volumetric modulated arc therapy
  2. aa:<70 or b:>70 years
  3. ba:<80 vs b:>80
  4. ca: Grade III glioma(anaplastic astrocytoma, Anaplastic oligodendroglioma, anaplastic oligoastrocytoma) vs b: Glioblastoma
  5. da: Gross total resection vs b: Partial resection or biopsy
  6. ea: MGMT negative or b: positive